SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 197 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.77 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $27 | -43.8% | 15,146 | 0.0% | 0.00% | – |
| Q4 2022 | $48 | -100.0% | 15,146 | -46.4% | 0.00% | -100.0% |
| Q2 2022 | $117,000 | -42.9% | 28,246 | -19.9% | 0.00% | 0.0% |
| Q1 2022 | $205,000 | -22.3% | 35,246 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $264,000 | -17.0% | 35,246 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $318,000 | -24.6% | 35,246 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $422,000 | +92.7% | 35,246 | +102.0% | 0.00% | +100.0% |
| Q1 2021 | $219,000 | -19.5% | 17,446 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $272,000 | +64.8% | 17,446 | 0.0% | 0.00% | +100.0% |
| Q3 2020 | $165,000 | -47.1% | 17,446 | -50.0% | 0.00% | 0.0% |
| Q2 2020 | $312,000 | -65.6% | 34,892 | -63.3% | 0.00% | -94.4% |
| Q1 2019 | $906,000 | -17.0% | 95,000 | 0.0% | 0.02% | -18.2% |
| Q4 2018 | $1,091,000 | -88.2% | 95,000 | -82.6% | 0.02% | -80.7% |
| Q3 2018 | $9,238,000 | +82.2% | 545,000 | +52.7% | 0.11% | +14.0% |
| Q2 2018 | $5,069,000 | – | 357,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |